Finding pathways to success in breast cancer
The last week brough a huge tsunami of data across varied topics ranging from hematologic malignancies (ASH), breast cancer (SABCS) and immunotherapies (ESMO IO) – we’re still digging our way out of it all!
There’s plenty of detailed analyses yet to come from all of these meetings, including some KOL interviews and thought provoking pieces to consider as well.
Here we look at some translational findings from academic researchers as well as companies involved in clinical trials in breast cancer. Yes, it’s time for some post SABCS reviews on a series of different topics…
To learn more from our oncology analysis and get a heads up on the latest insights and commentary pertaining to the SABCS meeting, subscribers can log-in or you can click to gain access to BSB Premium Content.
Remember the good old days at ESMO17 in Madrid? Sadly there’s no face to face networking at this year’s ESMO20 virtual meeting!
In this third ESMO 2020 Preview the focus is on early stage immunotherapies – we’ll cover targeted therapies in a separate review article.
As new regimens evolve involving multiple immune targets, this complexity brings with it a greater need to understand cell-cell interactions – not just immune cell relationships, but also oncogenic, metabolic, and even epigenetic ones. How do they all fit together and what happens when we interfere with those relationships therapeutically?
Often the simple answer is we don’t know until we head into the clinic, I’m afraid.
Beyond the obvious phase 3 IO readouts in the various Presidential symposia and Proffered oral sessions there are quite a few emerging ideas – old ones with a twist as well as entirely new ones – which we can consider and discuss.
Here, we highlight five key IO areas related to cancer immunotherapy and explore the various concepts as preparation for the upcoming meeting…
To learn more from our oncology analysis and get a heads up on insights and commentary pertaining to ESMO 2020, subscribers can log-in or you can click to gain access to BSB Premium Content.
Unlike last year, rain in San Francisco wasn’t a feature in 2019
If there’s anyone who hasn’t got fed up looking for somewhere to sit and chat or have a meeting in San Francisco at the 2019 JP Morgan Healthcare conference this week, then don’t be surprised…
With meeting space continually at a premium and many attendees unwilling to pay exhorbitant table rental prices, you now see people resorting to the lobby steps at the Sir Francis Drake, while the ladies have the advantage over the gents of access to the powder room in the Westin (with plugs!)
There’s also a movement from the chic to the shabby:
JPM is as much about informal meetings, pitches and confabs about new ideas, as it is about the actual CEO presentations, and so this situation is likely to continue in future years.
Meanwhile, we continue to dive in with our latest daily blog and put a bunch of companies through their paces. If day 1 is all about the big pharmas, by day 3 the focus is much more on up and coming or mid sized biotechs…
To learn more and get a heads up on our latest conference coverage, subscribers can log-in or you can click to gain access to BSB Premium Content.